Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma

Neeraj Agarwal, Joaquim Bellmunt, Benjamin L. Maughan, Kenneth M. Boucher, Toni K. Choueiri, Angela Q. Qu, Nicholas J. Vogelzang, Ronan Fougeray, Guenter Niegisch, Peter Albers, Yu Ning Wong, Yoo Joung Ko, Srikala S. Sridhar, Srinivas K. Tantravahi, Matthew D. Galsky, Daniel P. Petrylak, Ulka N. Vaishampayan, Amitkumar N. Mehta, Tomasz M. Beer, Cora N. SternbergJonathan E. Rosenberg, Guru Sonpavde

    Research output: Contribution to journalArticlepeer-review

    24 Scopus citations

    Fingerprint

    Dive into the research topics of 'Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma'. Together they form a unique fingerprint.

    Medicine & Life Sciences